IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Inclusion Criteria: * HLA A201 + phenotype * Biopsy-proven melanoma, Stages III (A, B and C) or stage IV.- no evidence of disease at study entry * Age: 21-75 years * ECOG performance status 0-1 * Adequate marrow function * Adequate hepatic function * Adequate renal function * Written informed consent Exclusion Criteria: * Subjects with measureable non-resectable melanoma * Subjects who have had chemotherapy less than 4 weeks before starting trial * Subjects who received IFN-a or GM-CSF less than 4 weeks before starting trial * Subjects who received IL2 less than 4 weeks before starting trial * Subjects with a baseline LDH greater than 1.1 times the ULN * Subjects who are HIV positive * Female subjects who are pregnant * Subjects who have received corticosteroids or other immunosuppressive agents less than 4 weeks before starting trial * Subjects who have asthma and/or are on treatment for asthma * Subjects with angina pectoris * Subjects with congestive heart failure * Subjects with history of autoimmune disease including lupus, rheumatoid arthritis or thyroiditis * Subjects with active infections including viral hepatitis * Subjects with a history of neoplastic disease othe than melanoma within the last 5 years * History of neoplastic disease within the last 5 years except for carcinoma in situ of the cervix, superficial bladder cancer or basal/squamous cell carcinoma of the skin. * Subjects who present with open wounds